Agios Pharmaceuticals Inc
AGIO
Market Cap$1.99B
Close$
$-9.81
128.5% downside
Current Fair Value
128.5% downsideOvervalued by 128.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.99 Billion |
|---|---|
| Enterprise Value | $1.96 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $11.86 |
| Beta | 0.73 |
| Outstanding Shares | 57,459,195 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 2.96 |
|---|---|
| PEG | 31.18 |
| Price to Sales | - |
| Price to Book Ratio | 1.38 |
| Enterprise Value to Revenue | 52.95 |
| Enterprise Value to EBIT | -4.44 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Agios Pharmaceuticals Inc
536 employees
CEO: Jacqualyn Fouse Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation b...